Most Read Articles
20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Audrey Abella, 21 Dec 2018
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Saras Ramiya, 23 Oct 2018
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Audrey Abella, 13 Dec 2018
The combination of the monoclonal antibody rituximab and the immunomodulatory agent lenalidomide (R2 regimen) showed significant survival advantage over single-agent rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), which includes follicular lymphoma (FL) and marginal zone lymphoma (MZL), according to the results of the AUGMENT* trial presented at ASH 2018.

Oral Xa inhibitors prevent recurrent venous thromboembolism in cancer patients

12 Oct 2018

Oral factor Xa inhibitors may be used as potential substitutes for warfarin and low molecular weight heparin for the prevention of recurrent thromboembolism in oncology patients, suggests a recent study. However, randomized controlled trials are warranted to confirm these results.

A total of 127 patients with venous thromboembolism were recruited, of whom 48 received rivaroxaban or apixaban, 23 received enoxaparin, and 56 received warfarin. Lung (21 percent), colorectal (14 percent) and breast (14 percent) were the three most common cancer diagnoses.

At 3 months, no difference was observed between the rivaroxaban/apixaban (0 percent), warfarin (3.6 percent) and the enoxaparin cohorts (4.4 percent; p=0.8319). Only one patient in the enoxaparin arm (4.2 percent) had a major bleeding at 3 months.

Moreover, mortality was 0 percent, 3.6 percent and 17.4 percent in the rivaroxaban/apixaban, warfarin and enoxaparin cohorts, respectively, at 3 months.

In another study, Xing and colleagues found that rivaroxaban was on a par with enoxaparin in terms of safety and efficacy for the prevention of recurrent venous thromboembolism in patients with malignancy, indicating rivaroxaban as a potential option for cancer patients with venous thromboembolism. [Medicine (Baltimore) 2018;97:e11384]

In this study, the authors used retrospectively obtained data to compare the recurrent venous thromboembolism incidence in oncology patients taking rivaroxaban/apixaban, enoxaparin or warfarin with at least 3 months of follow-up. Inclusion criteria for patients were as follows: active cancer, venous thromboembolism, and taking warfarin, enoxaparin or rivaroxaban/apixaban.

The first episode of recurrent venous thromboembolism at 3 months was the primary endpoint, while the secondary endpoints included recurrent venous thromboembolism after 6 months, major bleeding and mortality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Audrey Abella, 21 Dec 2018
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Saras Ramiya, 23 Oct 2018
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Audrey Abella, 13 Dec 2018
The combination of the monoclonal antibody rituximab and the immunomodulatory agent lenalidomide (R2 regimen) showed significant survival advantage over single-agent rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), which includes follicular lymphoma (FL) and marginal zone lymphoma (MZL), according to the results of the AUGMENT* trial presented at ASH 2018.